IDNA — IDNA Genomics Public Cashflow Statement
0.000.00%
- €81.15m
- €83.58m
- €0.48m
Annual cashflow statement for IDNA Genomics Public, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 7 W | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | 0.25 | -0.365 | -1.34 | -2.97 |
Depreciation | ||||
Amortisation | ||||
Non-Cash Items | 0.046 | 0.095 | 0.045 | 1.48 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | -0.479 | 1.05 | 1.05 | -1.32 |
Change in Accounts Receivable | ||||
Change in Inventories | ||||
Change in Accounts Payable | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -0.143 | 0.922 | -0.011 | -2.52 |
Capital Expenditures | -0.16 | -0.146 | -0.716 | -0.176 |
Purchase of Fixed Assets | ||||
Purchase / Acquisition of Intangibles | ||||
Other Investing Cash Flow Items | 0.048 | — | — | 2 |
Sale of Business | ||||
Cash from Investing Activities | -0.112 | -0.146 | -0.716 | 1.82 |
Financing Cash Flow Items | — | -0.095 | -0.131 | -0.145 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 0.214 | -0.801 | 0.682 | -0.265 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -0.041 | -0.024 | -0.045 | -0.96 |